2024-09-24 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**Company Overview:** Pfizer Inc. is a multinational pharmaceutical corporation that develops and manufactures medicines and vaccines. 

**1. Performance Comparison with S&P 500 (VOO):**

* **Cumulative Return (PFE):** -11.53%
* **Cumulative Return (VOO):** 133.1%
* **Performance Gap:** -144.63% (PFE is significantly underperforming compared to the S&P 500)
* **Relative Performance:** 0.0 (The current performance gap is at the minimum value recorded historically)

**2. Recent Price Action:**

* **Closing Price:** $29.31
* **5-Day Moving Average:** $29.59
* **20-Day Moving Average:** $29.16
* **60-Day Moving Average:** $29.16

**3. Technical Indicators:**

* **RSI:** 63.39 (Neutral, not overbought or oversold)
* **PPO:** 0.14 (Slight positive momentum)
* **Delta_Previous_Relative_Divergence:** -1.44 (Short-term downtrend)
* **Expected Return:** 15.25% (Potential maximum return over 5 years based on current investment)

**4. Recent Earnings and Outlook:**

| Date | EPS | Estimated EPS | 
|---|---|---|
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |
| 2023-08-01 | 0.67 | 0.56 |

**Analysis:**

* Pfizer has consistently exceeded earnings estimates over the past few quarters.
* The most recent quarter (ending July 30, 2024) saw EPS of $0.60, surpassing the estimate of $0.458. 
* The company continues to demonstrate strong performance, despite facing challenges in the post-pandemic market. 

**5. Summary:**

Pfizer is currently significantly underperforming the S&P 500. However, it has shown strong recent earnings results exceeding expectations. Technical indicators suggest neutral to slightly positive momentum with a short-term downtrend. While the company faces challenges, its strong earnings performance indicates potential for growth. The expected return of 15.25% over 5 years suggests a positive outlook for investors.  

**Recommendation:**

Given the recent earnings performance and potential for future growth, Pfizer could be considered for a long-term investment. However, it is crucial to monitor the company's performance and market trends closely to adjust investment strategies accordingly. 
